RETAIN: A Phase 2/3 Randomized, Placebo-Controlled Study to Evaluate the Efficacy of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Total Knee Arthroplasty (TKA)
Latest Information Update: 25 Nov 2025
At a glance
- Drugs PLG 0206 (Primary)
- Indications Bone and joint infections
- Focus Registrational; Therapeutic Use
- Acronyms RETAIN
- Sponsors Peptilogics
Most Recent Events
- 16 Oct 2025 According to Peptilogics media release, the company announced the completion of an oversubscribed $78 million Series B2 financing round. The funding will support the company's Phase 2/3 pivotal trial.
- 16 Oct 2025 New trial record